1/23
Flashcards covering the FDA drug development and approval process, pharmaceutical R&D costs, patent protection, U.S. vs. international drug pricing, the Sovaldi Hepatitis C case study, the uninsured population profile, safety net programs (Community Health Centers, VHA, Ryan White HIV/AIDS), and hospital uncompensated care dynamics.

What are the five steps of the FDA drug approval process in the United States?
On average, how long does it take for an experimental drug to travel from laboratory discovery to U.S. patients, and what is its compound attrition rate?
It takes 12 to 15 years on average. Only 5 out of every 5,000 compounds evaluated in preclinical testing advance to human clinical trials, and only 1 of those 5 tested in humans is ultimately approved.
How do the three phases of human clinical trials differ in duration, sample size, and primary purpose?
Phase I lasts approximately 1.5 years with 20 to 100 healthy volunteers to evaluate safety and dosage. Phase II lasts about 2 years with 100 to 500 patient volunteers to assess efficacy and identify side effects. Phase III lasts about 3.5 years with 1,000 to 5,000 patient volunteers to confirm clinical effectiveness and monitor long-term adverse reactions.
At what milestones in drug development are the Investigational New Drug (IND) and New Drug Application (NDA) filed with the FDA?
An Investigational New Drug (IND) application is filed after preclinical testing before Phase I clinical trials can begin in humans. A New Drug Application (NDA) is filed following completion of Phase III clinical trials to seek formal FDA review and market approval.
What market protections are granted by a chemical patent, and when does it expire?
A patent grants the manufacturer the exclusive legal right to market a specific chemical substance. It expires 20 years from the original date of filing, after which FDA-approved generic versions may enter the market and compete.
How did annual R&D spending by PhRMA member firms change between 1984 and 2019?
Annual research and development spending rose from under $10 billion in 1984 to over $80 billion in 2019 (measured in 2019 dollars).
Which three therapeutic drug classes accounted for the highest total U.S. retail prescription spending in 2019?
Oncologics (nearly $70 billion), Diabetes (around $66 billion), and Autoimmune agents (around $65 billion).
How does cost-sharing for high-cost specialty drug classes like oncology and multiple sclerosis contrast with respiratory medications?
For specialty brand medicines like oncology and multiple sclerosis, 94% and 95% of patient out-of-pocket spending comes from deductibles and coinsurance (with copays making up only 5%–6%). By comparison, asthma/COPD therapies have 56% of patient costs paid via fixed copays and 44% through deductibles/coinsurance.
What share of Americans report not taking prescribed medications due to out-of-pocket costs according to KFF survey data?
29% did at least one of the following in the prior 12 months: 19% did not fill a prescription, 18% substituted an over-the-counter medicine, and 12% cut pills in half or skipped prescribed doses.
How did per capita prescription drug spending in the U.S. compare to the average of comparable nations in 2019?
The U.S. spent $963 per capita on prescription drugs in 2019, which is more than double the comparable country average of $466 (e.g., Germany spent $770, Canada $590, and the United Kingdom $273).

According to this comparative diagram, what regulatory steps exist in most developed nations before selling a drug that are absent in the U.S. system?
Most countries have regulatory bodies that evaluate whether a drug is clinically 'Worthwhile' relative to existing therapies and formally negotiate its 'Price' before market distribution. In contrast, the United States system proceeds directly from proving a drug is 'Safe' to allowing it to be 'Sold'.
What clinical breakthrough did Gilead Sciences achieve with the 2013 FDA approval of Sovaldi (sofosbuvir)?
Sovaldi provided an oral once-daily curative treatment for Hepatitis C Virus (HCV) with an over 90% cure rate in a 12-week course, replacing older interferon regimens that had severe adverse effects and lower success rates.
What price did Gilead Sciences place on Sovaldi, and how did public and private insurers react?
Gilead priced Sovaldi at $84,000 per 12-week course of treatment (approximately $1,000 per pill). In response, Medicaid and private insurers severely restricted and rationed access, leading to initial denial rates of 4.6 out of 10 Medicaid patients, 1 out of 10 privately insured patients, and 0.5 out of 10 Medicare patients.
Under the Inflation Reduction Act (IRA) of 2022, what statutory factors must Medicare evaluate when negotiating drug prices?
What was the national uninsured rate for nonelderly Americans in 2024, and how did it change from previous years?
The uninsured rate for individuals aged 0–64 was 9.8% (~26 million people) in 2024, representing an increase from 9.5% in 2023 and the first nationwide rise in the uninsured rate since 2019.
Among the 25.3 million nonelderly uninsured Americans in 2023, what was the distribution of coverage eligibility?
• 32.2% were eligible for Marketplace tax credits • 24.9% were eligible for Medicaid • 19.1% were ineligible for financial help due to an affordable employer offer or Marketplace coverage • 18.4% were ineligible due to immigration status • 5.4% fell into the Medicaid coverage gap
How was the $33.9 billion in public funding for uncompensated care distributed between federal and state/local sources in 2017?
Federal funding provided $21.7 billion (including $10.3B from the Veterans Health Administration, $8.1B from Federal Medicaid, $2.3B from the Indian Health Service, and $1.1B from Community Health Centers). State and local funding provided $12.2 billion (including $9.9B in state/local programs, $2.0B in state/local Medicaid, and $0.3B in health centers).
What populations are served by the Community Health Center Program under Section 330 funding?
Health centers serve approximately 28 million high-need patients, including 24.9 million low-income individuals (≤200% of the Federal Poverty Level), 6.2 million uninsured individuals, 3.5 million residents in or near public housing, 1.4 million homeless individuals, and nearly 1 million agricultural workers.
What key administrative and clinical requirements must a Section 330 Community Health Center satisfy?
• Deliver comprehensive, culturally competent primary care and supportive services (such as transportation, translation, and health education) • Provide care to all patients regardless of ability to pay, using a sliding fee discount scale • Operate as a public entity or private non-profit governed by a patient-majority board (at least 51% consumer representation) • Adapt patient-centered systems tailored to medically underserved communities

Based on this infographic, what are the total enrollment and patient utilization statistics for the Veterans Health Administration (VHA)?
Out of an estimated 18.2 million U.S. veterans, only 50% (9.1 million) are enrolled in VA Health Care, and only about 34% (6.3 million unique patients) actually utilize VA health care services.
What are the eligibility requirements and funding level for the Ryan White HIV/AIDS Program?
Funded at $2.5 billion annually, it provides care and support services to over half of all Americans living with HIV. It acts as a safety-net payer of last resort, with approximately 20% of its recipients being completely uninsured.

What are the three categories of Patient Assistance Programs (PAPs), and which is barred from Medicare Part D?
What is Emergency Medicaid, and what policy change prompted its modern form?
Under the 1996 welfare reform law, lawful permanent residents were subjected to a 5-year waiting ban before becoming eligible for full Medicaid coverage. To prevent hospitals from bearing all emergency costs, Congress established Emergency Medicaid as an exception to reimburse emergency treatment costs for low-income non-citizens who otherwise meet Medicaid income thresholds.
How did hospital uncompensated care burdens diverge between Medicaid expansion and nonexpansion states following the ACA?
In Medicaid expansion states, hospital uncompensated care fell sharply from around 4.5% of operating costs in 2013 to roughly 3.0% in 2014. In nonexpansion states, uncompensated care remained persistently high at approximately 5.4%–5.5%, driving higher risks of rural hospital closures.